Furthermore, we exploited the use of EVs that were non-genetically modified with an IL-4R-targeting peptide, IL4RPep-1, using DOPE-BAM to target IL-4Rs in anaplastic thyroid cancer. This evidence concerns the gene IL4R and thyroid gland undifferentiated (anaplastic) carcinoma.